Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

Peter Schmid, Sylvia Adams, Hope S. Rugo, +14

New England Journal of Medicine

Pembrolizumab for Early Triple-Negative Breast Cancer

Peter Schmid, Javier Cortés, Lajos Pusztai, +18

New England Journal of Medicine

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Javier Cortés, David W. Cescon, Hope S. Rugo, +224

The Lancet

Chemotherapy Versus PlaceboBreast OncologyOncologyClinical TrialsBreast Cancer +5

Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

Peter Schmid, Hope S. Rugo, Sylvia Adams, +11

The Lancet Oncology

Breast OncologyOncologyMedicineBreast CancerPharmacotherapy +5

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

Javier Cortés, Hope S. Rugo, David W. Cescon, +16

New England Journal of Medicine

Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer

Leisha A. Emens, Cristina Cruz, Joseph P. Eder, +16

JAMA Oncology

Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study

Sylvia Adams, Sherene Loi, Deborah Toppmeyer, +17

Annals of Oncology

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim, +148

The Lancet Oncology

MedicineImmunologyPathologyImmune Checkpoint InhibitorCancer Treatment +3

Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer

Tiffany A. Traina, Kathy D. Miller, Denise A. Yardley, +17

Journal of Clinical Oncology

Androgen ReceptorBreast OncologyMedicineCancer ManagementMetronomic Therapy +13

Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial

Eric P. Winer, Oleg Lipatov, Seock‐Ah Im, +17

The Lancet Oncology

Breast OncologyOncologyClinical TrialsPathologyImmune Checkpoint Inhibitor +5